The US pneumococcal vaccine market size is expected to reach USD 6,511.79 million by 2034, exhibiting a CAGR of 2.3% during the forecast period.
The US Pneumococcal Vaccine Market plays a vital role in preventing serious illnesses caused by Streptococcus pneumoniae. Pneumococcal infections, ranging from mild respiratory diseases to life-threatening conditions like pneumonia, meningitis, and sepsis, remain a significant public health concern in the United States. Vaccination programs have been pivotal in reducing morbidity and mortality associated with these infections.
Market Growth Drivers
- Rising Incidence of Pneumococcal Diseases
Despite improvements in healthcare, pneumococcal infections remain prevalent, particularly among vulnerable populations such as children, the elderly, and immunocompromised individuals. - Expanding Immunization Programs
Government initiatives like the Vaccines for Children (VFC) program and Medicare coverage for adult vaccines have increased accessibility and uptake of pneumococcal vaccines. - Development of Next-Generation Vaccines
Pharmaceutical companies are investing in the development of vaccines with broader strain coverage, such as Pfizer’s Prevnar 20, which targets additional serotypes not covered by earlier versions.
Download Free Sample PDF Copy of the Report:
List of Key Players in US Pneumococcal Vaccine Market
- Pfizer Inc.
- Merck & Co., Inc.
- Sanofi
- GlaxoSmithKline plc
- CSL Behring
- Serum Institute
- Astellas Pharma US, Inc.
- Johnson & Johnson
Key Trends
- Introduction of Multi-Valent Vaccines
Recent innovations focus on increasing the number of strains covered, enhancing vaccine efficacy across diverse populations. - Combination Vaccines
Efforts to combine pneumococcal vaccines with other routine immunizations are underway to simplify vaccination schedules. - Focus on Pediatric and Adult Immunization
Expanded guidelines for vaccinating both pediatric and adult populations, including those with underlying health conditions, are influencing market dynamics.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:
The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.
By Vaccine Type Outlook (Revenue – USD Million, 2020 – 2034)
- Pneumococcal conjugate vaccine
- Pneumococcal polysaccharide vaccine
By Product Type Outlook (Revenue – USD Million, 2020 – 2034)
- Prevnar 13
- Synflorix
- Pneumovax23
By End User Outlook (Revenue – USD Million, 2020 – 2034)
- Public Sector
- Private Sector
Recent Developments in the Industry
March 2024: Vaxcyte, Inc. successfully registered participants in their trial, a phase II study, while assessing VAX-24, a pneumococcal conjugate vaccine (PCV) composed of 24 valences that are tested among healthy infants. The firm intends to communicate topline safety, tolerability, and immunogenicity findings for the initial 3 dose series by the first quarter of 2025 and for the booster dose by 2025.
October 2023: Lonza and Vaxcyte, a US clinical-stage vaccine innovation company, expanded their partnership to increase manufacturing facility Vaxcyte’s pneumococcal conjugate vaccine (PCV) candidates.
April 2022: Merck announced that the US Food and Drug Administration (FDA) is giving a breakthrough therapy designation to V116, an investigational 21-valent pneumococcal conjugate vaccine that will prevent invasive pneumococcal disease and pneumococcal pneumonia in adults.
The US Pneumococcal Vaccine Market is a critical segment of the healthcare industry, ensuring protection against one of the most significant causes of infectious disease-related mortality. With continuous advancements in vaccine technology, supportive public health initiatives, and growing awareness, the market is poised for sustained growth.